Study to examine environmental factors, changes in SP | Health ...

The study design will include new genetic variations that have been associated with the risk of developing multiple sclerosis, as well as genes that determine the levels and responses to environmental factors. MS patients will be divided into two equal groups: a training group that will be used to identify gene-environment interactions, and a group that will be used to reproduce the result of the training group.Identification of gene-environment interactions is critical to the development of improved strategies to slow the progression of multiple sclerosis, because it might allow patients with pre-existing genetic risk factors to reduce the rate of progression of the disease by changing lifestyle, says Ramanathan .

The two-year project, led by Murali Ramanathan, Ph.D., tested the hypothesis that the metabolism of nicotine by-products of metabolism and increased levels of anti-Epstein-Barr virus , every interaction with variations in specific genes lead to increased neurodegeneration and an increase in lesions in MS patients.

Bianca Weinstock-Guttman, MD, Robert Zivadinov, MD, Ph.D., and Jun Qu, Ph.D., UB all are co-principal investigators. Dana Horakova, MD, Ph.D.D., are employees of the Charles University in Prague.

The research aims to identify gene-environment interactions between the key molecules in the way of vitamin D, anti-Epstein-Barr virus, smoking and the main genetic variants involved in the conversion of patients with a clinically isolated syndrome for the final MS.

Patients were stabilized on atorvastatin 10 mg / day for six weeks and then were randomized to treatment with ezetimibe 10 mg / day and atorvastatin 10 mg / day for 12 weeks or atorvastatin 20 mg / day for six weeks, followed by a fourfold of atorvastatin 40 mg / day for six weeks. Significantly more patients reached their lipid goal with ezetimibe and atorvastatin combination compared to monotherapy or quadruple with a double dose atorvastatin. For example, the %age of patients achieving their target LDL-C on the combination of ezetimibe / atorvastatin at 12 weeks was 60.5 percent versus 49.7 percent for patients on atorvastatin 20mg/40mg [Odds ratio 1.21, 1.98)].

Ramanathan is a professor of pharmaceutical sciences and neurology at the Faculty of Pharmacy and Pharmaceutical Sciences and the Faculty of Medicine and Biomedical Sciences, respectively.

A grant of $ 634 000 from the Department of Defense allows researchers to investigate the University of Buffalo, a trio of environmental factors and their influence on the progression.

Source: http://www.exercise24.org/?p=231

michelle rounds michelle rounds cabin in the woods dan quayle brett favre packers stock packers stock